Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
NCT ID: NCT00218556
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2004-01-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients
NCT00655226
A Trial to Reduce Hepatitis C Among Injection Drug Users - 1
NCT00218192
Treatment of Hepatitis C in Psychiatric Patients
NCT00751426
Herbal Treatment of Hepatitis C in Methadone Maintained Patients
NCT00010816
VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
NCT00108563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We expect that, relative to the SC condition, participants randomized to the CBT-D condition will have decreased likelihood of depression-related antiviral treatment failure, will report lower levels of depressive symptoms, will complete more IFN injections, will have lower HCV RNA levels, and will have fewer illicit drug use days. If the efficacy of this intervention can be established in this trial and in subsequent clinical trials, MMT patients who elect to undergo antiviral therapy will have a valuable adjunct or alternative to the use of antidepressants to prevent depression. If found to be efficacious, this intervention will maximize the receipt of IFN treatment by MMT patients, thereby aiding in the prevention of liver failure, hepatocellular carcinoma, and liver-related death among those with HCV.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Depression prevention
Cognitive behavioral treatment for depression.
Cognitive behavioral treatment for depression
Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
Control
Treatment as usual.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive behavioral treatment for depression
Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Enrolled in MMT for at least 6 months
Exclusion Criteria
* Current suicidality
* Currently taking antidepressant medication
* Received HCV treatment in past
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rhode Island Hospital
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Associate Professor (Research)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan E Ramsey, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Rhode Island Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rhode Island Hospital
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01-16797-1
Identifier Type: -
Identifier Source: secondary_id
NIDA-16797-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.